Investigational drug · Phase 2
TRD205
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Postoperative Analgesia After Unilateral Hip Arthroplasty, Chronic Postoperative Neuralgia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
5
Any phase or sponsor naming "TRD205"
First trial start
2025
Apr 9, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TRD205", any sponsor or status.
Conditions studied
As listed on its trial records.
- Postoperative Analgesia After Unilateral Hip Arthroplasty
- Chronic Postoperative Neuralgia
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "TRD205" as an intervention, largest first.
- Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)Pivotal-lookingRecruiting
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07543796 · 200 participants (planned) · Start Apr 12, 2026 · Primary completion Dec 14, 2026
Drug: TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses; TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses and 3 more · For: Postoperative Analgesia After Unilateral Hip Arthroplasty
Sites: Guangzhou, China
- To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative NeuralgiaPivotal-lookingEnrolling by invitation
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07123402 · 184 participants (planned) · Start Apr 9, 2025 · Primary completion Apr 20, 2026
Drug: TRD205 tablets; TRD205 tablets and 2 more · For: Chronic Postoperative Neuralgia
Sites: Beijing, China
- Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy VolunteersPivotal-lookingCompleted
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07123428 · 151 participants · Start Jan 26, 2024 · Primary completion Nov 27, 2024
Drug: TRD205; Placebo · For: Healthy
Sites: Changchun, China
- To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip ArthroplastyNot yet recruiting
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07121101 · 40 participants (planned) · Start Sep 26, 2025 · Primary completion Nov 20, 2025
Drug: TRD205 tablets; TRD205 tablets and 2 more · For: Postoperative Analgesia After Unilateral Hip Arthroplasty
Sites: Guangzhou, China
- To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hallux Valgus Orthopedic SurgeryNot yet recruiting
Beijing Tide Pharmaceutical Co., LtdIndustry
NCT07121023 · 32 participants (planned) · Start Aug 26, 2025 · Primary completion Dec 27, 2025
Drug: TRD205 tablets; TRD205 tablets and 2 more · For: Postoperative Analgesia After Unilateral Hallux Valgus Correction Surgery
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.